Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

AdAlta Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

AdAlta şirketinin toplam hissedar öz sermayesi A$2.0M ve toplam borcu A$2.6M olup, bu da borç-öz sermaye oranını 128.3% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla A$5.6M ve A$3.5M dir.

Anahtar bilgiler

128.3%

Borç/özkaynak oranı

AU$2.61m

Borç

Faiz karşılama oranı	n/a
Nakit	AU$3.13m
Eşitlik	AU$2.03m
Toplam yükümlülükler	AU$3.54m
Toplam varlıklar	AU$5.57m

Son finansal sağlık güncellemeleri

Recent updates

Shareholders May Find It Hard To Justify Increasing AdAlta Limited's (ASX:1AD) CEO Compensation For Now

Nov 16

Is AdAlta (ASX:1AD) Using Debt Sensibly?

Sep 02

We're Not Very Worried About AdAlta's (ASX:1AD) Cash Burn Rate

Jun 11

Companies Like AdAlta (ASX:1AD) Are In A Position To Invest In Growth

Feb 26

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 1AD 'nin kısa vadeli varlıkları ( A$5.3M ) kısa vadeli yükümlülüklerini ( A$2.2M ) aşıyor.

Uzun Vadeli Yükümlülükler: 1AD şirketinin kısa vadeli varlıkları ( A$5.3M ) uzun vadeli yükümlülüklerini ( A$1.3M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 1AD şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 1AD şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 128.3% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 1AD şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: 1AD un, serbest nakit akışı her yıl % 0 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

AdAlta Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is AdAlta (ASX:1AD) Using Debt Sensibly?

We're Not Very Worried About AdAlta's (ASX:1AD) Cash Burn Rate

Companies Like AdAlta (ASX:1AD) Are In A Position To Invest In Growth

Recent updates

New major risk - Shareholder dilution

New major risk - Financial position

AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 1.66 million.

AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 1.66 million.

New major risk - Financial position

AdAlta Limited has filed a Follow-on Equity Offering in the amount of AUD 1.23 million.

AdAlta Limited, Annual General Meeting, Nov 22, 2023

New major risk - Financial position

AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 3.153759 million.

First half 2023 earnings released: AU$0.009 loss per share (vs AU$0.015 loss in 1H 2022)

Shareholders May Find It Hard To Justify Increasing AdAlta Limited's (ASX:1AD) CEO Compensation For Now

Less than half of directors are independent

AdAlta Limited Provides an Update on Its Lead Program, AD-214

AdAlta Limited, Annual General Meeting, Nov 22, 2022

AdAlta Limited, Annual General Meeting, Nov 22, 2022

Is AdAlta (ASX:1AD) Using Debt Sensibly?

Full year 2022 earnings released: AU$0.022 loss per share (vs AU$0.024 loss in FY 2021)

AdAlta Limited Modifies the Sequencing of AD-214 Manufacturing Campaigns and Toxicology Studies

Price target increased to AU$0.27

Less than half of directors are independent

Adalta Limited Finalizes Reclinical Development Program to Develop Inhaled Version of AD-214

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 1.253406 million.

Full year 2021 earnings released: AU$0.024 loss per share (vs AU$0.037 loss in FY 2020)

We're Not Very Worried About AdAlta's (ASX:1AD) Cash Burn Rate

First half 2021 earnings released: AU$0.021 loss per share (vs AU$0.037 loss in 1H 2020)

Companies Like AdAlta (ASX:1AD) Are In A Position To Invest In Growth

AdAlta Receives Orphan Drug Designation from the US Food and Drug Administration for Its Lead Product Candidate AD-214 for the Treatment of Idiopathic Pulmonary Fibrosis

AdAlta Limited Announces Phase I HV Extension to Explore Encouraging Results

AdAlta Limited Announces the Extension of its Collaboration with GE Healthcare

AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 4 million.

AdAlta Limited has completed a Follow-on Equity Offering in the amount of AUD 4.09864 million.

Full year earnings released - AU$0.037 loss per share

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin